Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression ofE. coli nitroreductase

This publication has 15 references indexed in Scilit:

• Adenoviral delivery of B7–1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells
  Gene Therapy, 1998
• The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable Metabolite
  Human Gene Therapy, 1997
• Selective cell ablation in transgenic mice expressing E. coli nitroreductase
  Gene Therapy, 1997
• The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954
  Gene Therapy, 1997
• Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
  European Journal Of Cancer, 1995
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—II: A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase
  Biochemical Pharmacology, 1992
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I
  Biochemical Pharmacology, 1992
• Bioactivation of CB 1954: Reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species
  Biochemical Pharmacology, 1991
• Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.
  Proceedings of the National Academy of Sciences, 1991
• A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells
  Biochemical Pharmacology, 1988